Biotech ETFs present attractive, lower-correlated growth opportunities as valuations remain modest and M&A plus AI-driven drug discovery could catalyze further gains.
Two Sector ETFs Are Quietly Outperforming the S&P 500 Without a Single AI Stock
Concentration in Magnificent 7 AI stocks raises bubble risk; retirees should consider diversifying into non-AI ETFs such as biotech (XBI) and silver/miners (SLVP).